stockportfolio.pro
Stocks / ATRC vs URGN
ATRC vs URGN
AtriCure, Inc. and UroGen Pharma Ltd. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AtriCure, Inc. (ATRC) | UroGen Pharma Ltd. (URGN) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $534.53M | $109.79M |
| Net income (latest FY) | $-11.45M | $-153.49M |
| Revenue growth (5y CAGR) | 20.9% | 56.2% |
| Net margin | -2.1% | -139.8% |
| Return on equity | -2.3% | 145.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ATRC — free Open URGN — freeFrequently asked questions
Which is bigger, ATRC or URGN?
AtriCure, Inc. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, ATRC or URGN?
Over the last five fiscal years, UroGen Pharma Ltd. grew revenue faster — 56.2%/yr versus 20.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.